|
|
 Previous Article | Table of Contents | Next Article 
Putative oncogenic role of the erythropoietin receptor in murine and human
erythroleukemia cells
S Chretien, F Moreau-Gachelin, F Apiou, G Courtois, P Mayeux, B Dutrillaux, JP Cartron, S Gisselbrecht and C Lacombe
Institut National de Transfusion Sanguine et Unite INSERM U76, Paris,
France.
To determine whether the erythropoietin receptor (Epo-R) plays a role in
the course of malignant erythropoietic disorders, this gene was studied in
murine and human erythroleukemia cells. An altered Epo-R gene was found in
a murine Friend erythroleukemia cell line, FCL1, due to a spleen
focus-forming virus (SFFV) long terminal repeat insertion within the
noncoding region of the first exon, leading to Epo-R mRNA overexpression. A
similar mechanism of Epo-R activation has previously been described in the
T3CL-2 Friend erythroleukemia cell line. An elevated number of Epo-binding
sites has been observed in two human erythroleukemia cell lines, TF-1 and
UT7. In UT7 cells, homogeneously staining region of the short arm of
chromosome 19 [hsr (19)] was evidenced, which contained an amplification of
the Epo-R gene. This Epo- R gene amplification was confirmed by the
quantification of Southern blots in which the intensity of the Epo-R signal
was compared in UT7 DNA and in DNA from normal cells. The Epo-R gene was
present in UT7 at a mean number of seven to eight copies per cell.
Interestingly, the Epo- R gene was rearranged; the breakpoint region was
located near the 3' end of the gene, 3 kb downstream from the end of the
last exon. Taken together, these results suggest that, in both murine and
human systems, genetic alterations of the Epo-R gene are not rare events
and could be involved in the occurrence of the erythroleukemic process.
Volume 83,
Issue 7,
pp. 1813-1821,
04/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. M. Fine, M. Stanulla, M. Schrappe, M. Ho, S. Viehmann, J. Harbott, and L. M. Boxer
Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia
Blood,
February 1, 2004;
103(3):
1043 - 1049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-M. Huang, J.-C. Li, Y.-C. Hsieh, H.-F. Yang-Yen, and J. J.-Y. Yen
Optimal Proliferation of a Hematopoietic Progenitor Cell Line Requires Either Costimulation With Stem Cell Factor or Increase of Receptor Expression That Can Be Replaced by Overexpression of Bcl-2
Blood,
April 15, 1999;
93(8):
2569 - 2577.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kirito, M. Uchida, M. Takatoku, K. Nakajima, T. Hirano, Y. Miura, and N. Komatsu
A Novel Function of Stat1alpha and Stat3 Proteins in Erythropoietin-Induced Erythroid Differentiation of a Human Leukemia Cell Line
Blood,
July 15, 1998;
92(2):
462 - 471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. Gonda and R. J. D'Andrea
Activating Mutations in Cytokine Receptors: Implications for Receptor Function and Role in Disease
Blood,
January 15, 1997;
89(2):
355 - 369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Namikawa, M. Muench, and M. Roncarolo
Regulatory roles of the ligand for Flk2/Flt3 tyrosine kinase receptor on human hematopoiesis
Stem Cells,
July 1, 1996;
14(4):
388 - 395.
[Abstract]
|
|
|
|
|
|
|
F. Verdier, P. Walrafen, N. Hubert, S. Chretien, S. Gisselbrecht, C. Lacombe, and P. Mayeux
Proteasomes Regulate the Duration of Erythropoietin Receptor Activation by Controlling Down-regulation of Cell Surface Receptors
J. Biol. Chem.,
June 9, 2000;
275(24):
18375 - 18381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
